- Home
- IONS vs ACA Comparison
IONS vs ACA Comparison
Compare IONS & ACA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- ACA
- Stock Information
- Founded
- IONS 1989
- ACA 2018
- Country
- IONS United States
- ACA United States
- Employees
- IONS N/A
- ACA N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- ACA Metal Fabrications
- Sector
- IONS Health Care
- ACA Industrials
- Exchange
- IONS Nasdaq
- ACA Nasdaq
- Market Cap
- IONS 4.6B
- ACA 4.8B
- IPO Year
- IONS 1991
- ACA N/A
- Fundamental
- Price
- IONS $32.26
- ACA $87.00
- Analyst Decision
- IONS Buy
- ACA Strong Buy
- Analyst Count
- IONS 18
- ACA 4
- Target Price
- IONS $57.41
- ACA $105.50
- AVG Volume (30 Days)
- IONS 1.7M
- ACA 274.2K
- Earning Date
- IONS 04-30-2025
- ACA 05-06-2025
- Dividend Yield
- IONS N/A
- ACA 0.23%
- EPS Growth
- IONS N/A
- ACA N/A
- EPS
- IONS N/A
- ACA 1.59
- Revenue
- IONS $717,253,000.00
- ACA $2,603,300,000.00
- Revenue This Year
- IONS N/A
- ACA $13.58
- Revenue Next Year
- IONS $27.39
- ACA $6.58
- P/E Ratio
- IONS N/A
- ACA $54.51
- Revenue Growth
- IONS N/A
- ACA 10.44
- 52 Week Low
- IONS $23.95
- ACA $68.11
- 52 Week High
- IONS $52.34
- ACA $113.43
- Technical
- Relative Strength Index (RSI)
- IONS 57.55
- ACA 62.43
- Support Level
- IONS $31.66
- ACA $81.59
- Resistance Level
- IONS $33.98
- ACA $88.20
- Average True Range (ATR)
- IONS 1.30
- ACA 2.71
- MACD
- IONS 0.41
- ACA 1.01
- Stochastic Oscillator
- IONS 68.84
- ACA 90.68
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About ACA Arcosa Inc.
Arcosa Inc is a manufacturer and producer of infrastructure-related products and services. It operates in three segments: Construction Products, Engineered Structures, and Transportation Products. The Construction Products segment produces and sells construction aggregates and manufactures and sells trench shields and shoring products and services for infrastructure-related projects. The Transportation Products segment manufactures and sells products for the inland waterway and rail transportation industries. The Engineered Structures segment manufactures and sells products for energy-related businesses, including structural wind towers, telecommunication structures, steel utility structures for electricity transmission and distribution, and storage and distribution containers.